We are international
Donate
TEXT SIZE   


International Myeloma Foundation (IMF) Accelerates Global Expansion with Appointment of Prof. Jean-Luc Harousseau MD

Renowned researcher to help accelerate IMF programs in Asia and Europe

01.07.16

NORTH HOLLYWOOD, Calif., January 7, 2016 – The International Myeloma Foundation (IMF) – improving the quality of life of myeloma patients while working toward prevention and a cure – is pleased to announce that renowned French myeloma researcher Prof. Jean-Luc Harousseau, MD is joining the organization to help accelerate the IMF’s global expansion and outreach efforts in Asia and Europe.

“I am thrilled and honored that Prof. Harousseau is joining our global team,” said IMF President Susie Novis Durie. “As Medical Education and Research Consultant, Dr. Harousseau’s background and expertise will enhance our global programs. We’ve had the pleasure of working closely with Dr. Harousseau for many many years, and he’s been a dear friend – not only to the IMF, but to myeloma patients around the world.”

“Jean-Luc Harousseau brings extensive experience in myeloma treatment and research to his new position with the IMF,” said IMF Chairman Dr. Brian Durie. “In addition, his experience on the global stage makes him perfectly suited to playing an important role in our growing patient education and outreach efforts around the world.”

Recently retired from his position as professor of hematology at the University of Nantes, France—a position he held since 1980—Prof. Harousseau served as Chairman of the French National Authority for Health (HAS) from 2011 through 2015. He served as Director of the Cancer Center Rene Gauducheau in Nantes from 2008 to 2011. From 1984 to 2008, Prof. Harousseau was Head of the Department of Hematology at University Hospital.

Prof. Harousseau was a founding member and served as President of the Intergroupe Français du Myélome (IFM), whose clinical trials have contributed significantly to the major improvements in the prognosis of myeloma. Recipient of the 2005 Waldenström Award and the 2009 Robert A. Kyle Lifetime Achievement Award for his work in the field of multiple myeloma, he has contributed to more than 500 peer-reviewed publications, including the New England Journal of Medicine, Blood, and the Journal of Clinical Oncology.

In his new role with the IMF, Prof. Harousseau will help increase access to treatment for myeloma patients globally. His vast experience working with policymakers in France gives him the credentials and inside knowledge to make change happen. “France has an independent body in charge of improving quality of care and patient safety,” he said. “One of its most important roles is to evaluate the benefit/risk ratio and the efficiency of new drugs in order to make decisions about their reimbursement and pricing.”

ABOUT THE INTERNATIONAL MYELOMA FOUNDATION 

Celebrating its 25th anniversary, the International Myeloma Foundation (IMF) is the oldest and largest foundation focusing specifically on multiple myeloma. The Foundation’s reach extends to more than 400,000 members in 140 countries worldwide. The IMF is dedicated to improving the quality of life of myeloma patients while working toward prevention and a cure by focusing on four key areas: research, education, support, and advocacy. The IMF has conducted more than 250 educational seminars worldwide, maintains a world-renowned InfoLine, and in 2001, established the International Myeloma Working Group (IMWG), a collaborative research initiative focused on improving myeloma treatment options for patients. In 2013, the IMF launched the Black Swan Research Initiative®, a groundbreaking research project aimed at curing myeloma. The IMF can be reached at (800) 452-CURE (2873). The global website is www.myeloma.org. Follow the IMF on Twitter @IMFmyeloma.

CONTACT:

Debra Gendel
(310) 710-1903
Cashmere Road Media
debra@cashmereroad.com


 related articles
The IMF’s Internatio...
International Myelom...
International Myelom...
International Myelom...
Everybody Loved Dori...
International Myelom...
International Myelom...
International Myelom...
The International My...
International Myelom...
Generous Donations H...
International Myelom...
The International My...
Members of Internati...
The International My...
International Myelom...
The International My...
The International My...
The International My...
International Myelom...
International Myelom...
International Myelom...
International Myelom...
Dr. Brian Durie, Cha...
International Myelom...
Study Results Publis...
The International My...
The International My...
Freelite and Hevylit...
The IMF says Imnovid...
The International My...
International Myelom...
International Myelom...
IMF's Michael S. Kat...
The IMF Reaches Out ...
The International My...
The International My...
The International My...
The International My...
Latest Myeloma Resea...
The International My...
IMF: NEWLY PUBLISHED...
2013 Robert A. Kyle ...
The International My...
The International My...
International Myelom...
Patients Equal Acces...
The International My...
Medical Innovation i...
The International My...
The International My...
THE INTERNATIONAL MY...
THE INTERNATIONAL MY...
THE INTERNATIONAL MY...
THE INTERNATIONAL MY...
FDA Recognition of E...
The International My...
The International My...
The International My...
Nurse Leaders within...
The International My...
IMF supports legisla...
Inaugural Summit of ...
ASCO Presentations P...
First Anniversary Of...
The International My...
The International My...
A Patient Advocacy C...
The International My...
The International My...
The International My...
Statement from the I...
The International My...
The International My...
Dr. Brian Durie Rece...
The International My...
The International My...
Continuing Her Husba...
International Myelom...
OncLive: Project Aim...
Onclive: Charting th...
Dr. Brian Durie Feat...
When myeloma awarene...
IMF Advocates Join T...
IMF Chairman Dr. Bri...
Patient Advocacy Mes...
Dr. Durie interviewe...
Dr. Durie interviewe...
Susie Novis Intervie...
Mozobil™ Approval Co...
THE INTERNATIONAL MY...
THE INTERNATIONAL MY...
THE INTERNATIONAL MY...
THE INTERNATIONAL MY...
THE INTERNATIONAL MY...
THE INTERNATIONAL MY...
THE INTERNATIONAL MY...
THE INTERNATIONAL MY...
THE INTERNATIONAL MY...
THE INTERNATIONAL MY...
NURSE LEADERSHIP BOA...
THE INTERNATIONAL MY...
THE INTERNATIONAL MY...
IMF PRESENTS THE KYL...
THE IMF SAYS NEWLY D...
THE INTERNATIONAL MY...
THE INTERNATIONAL MY...
THE INTERNATIONAL MY...
THE INTERNATIONAL MY...
Major Medical Confer...
THE INTERNATIONAL MY...
THE INTERNATIONAL MY...
THE INTERNATIONAL MY...
The International My...
THE NURSE LEADERSHIP...
THE INTERNATIONAL MY...
THE INTERNATIONAL MY...
STUDY SHOWS VELCADE&...
New England Journal ...
THE INTERNATIONAL MY...
IMF REPORTS POSITIVE...
THE INTERNATIONAL MY...
THE INTERNATIONAL MY...
IMF Says Revlimid Ap...
THE INTERNATIONAL MY...
INDEPENDENT SURVEY R...
LEADING CANCER EXPER...
The International My...
BANK ON A CURE
THE INTERNATIONAL MY...
The International My...
Leading Cancer Exper...
IMF DNA BANK IDENTIF...
New, Improved Stagin...
IMF to Bring Highlig...
IMF Receives Four-St...
GREAT NEWS: Revlimid...
IMF Applauds Medicar...
Kenneth C. Anderson,...
IMF Receives Million...
IMF Raises Awareness...
International Myelom...
International Myelom...
Foremost Myeloma Org...
Webcast of the Offic...
Bank On A Cure® Laun...
Bank On A Cure® Que...
Bank On a Cure® Freq...
Bank On A Cure® Scie...
International Myelom...
IMF Patient Programs...
Bank On A Cure® Bria...
Bank On A Cure® on t...
Brian G.M. Durie, M....
Susie Novis Durie

The IMF’s International Myeloma Working Group Establishes Updated Yardstick for Disease Assessment in the Evolving Treatment Landscape of 2016
International Myeloma Foundation Brings Together 100 of the World’s Top Myeloma Experts June 7-9, 2016 in Copenhagen for 7th Annual Summit
International Myeloma Foundation Honors Dr. S. Vincent Rajkumar With the 2016 Robert A. Kyle Lifetime Achievement Award
International Myeloma Foundation (IMF) Says Controversial Drug Cost Report Could Limit Patient Access to Optimal Treatment
Everybody Loved Doris: An IMF Tribute
International Myeloma Foundation (IMF) Funds First Large-Scale Screening to Identify and Treat Precursor of Blood Cancer Before Disease Develops
International Myeloma Foundation (IMF) Marches Toward a Cure with Takeda Oncology’s ‘Music 2 Fight Myeloma’ Initiative for ‘Myeloma ACTION Month’
International Myeloma Foundation (IMF) Declares March Myeloma Action Month
The International Myeloma Foundation (IMF) Appoints Dr. Rafat Abonour as New Medical Liaison to Support Organization’s European Program Expansion
International Myeloma Foundation (IMF) Accelerates Global Expansion with Appointment of Prof. Jean-Luc Harousseau MD
Generous Donations Help Fund 2016 Brian D. Novis Research Grants
International Myeloma Foundation Scores Support in Takeda Oncology’s ‘3 Points for Patients’ Campaign Partnership with NBA’s Boston Celtics
The International Myeloma Foundation (IMF) Announces Publication of New Diagnostic Guidelines to Better Assess Patients and Guide Treatment
Members of International Myeloma Foundation’s Nurse Leadership Board Author Key Textbook for Nurses
The International Myeloma Foundation Applauds Bipartisan Introduction of Oral Parity Legislation
International Myeloma Foundation Brings Together 100 of the World’s Top Myeloma Experts June 8-10 in Vienna, Austria for 6th Annual Summit
The International Myeloma Foundation Mourns the Passing of Board of Directors Member, Patient Champion, Michael S. Katz
The International Myeloma Foundation (IMF) Announces Another Successful Myeloma Awareness Month (#MAM)
The International Myeloma Foundation (IMF) Secures the Introduction of a Federal Resolution Recognizing March 2015 as “National Multiple Myeloma Awareness Month”
International Myeloma Foundation Honors Prof. Dr. Pieter Sonneveld With 2015 Robert A. Kyle Lifetime Achievement Award
International Myeloma Foundation Declares March “Myeloma Awareness Month”
“Knowledge is Power” Is Key Message of Month-Long Awareness Campaign
International Myeloma Foundation Expresses Disappointment at Oncologic Drugs Advisory Committee (ODAC) Recommendation Against New Myeloma Treatment Panobinostat
International Myeloma Foundation’s Research Division Issues New Guidelines for Early Diagnosis of Multiple Myeloma
Dr. Brian Durie, Chairman of the International Myeloma Foundation, Honored by Mayo Clinic With Distinguished Alumni Award
International Myeloma Foundation Hosts Congressional Briefing on Environmental Exposures, Such as Toxins at 9/11 World Trade Center Site, and Myeloma
Study Results Published Showing Advantages with Revlimid in Newly Diagnosed Myeloma
The International Myeloma Foundation (IMF) Celebrates Maine’s Oral Anticacer Treatment Access Law Taking Effect
The International Myeloma Foundation Unveils New Logo
Freelite and Hevylite will help the Black Swan Research Initiative find the best treatment to cure multiple myeloma
The IMF says Imnovid® (pomalidomide), the newest medication for advanced cases of multiple myeloma, is approved for reimbursement in Sweden, Spain, and Switzerland
The International Myeloma Foundation (IMF) Applauds Ohio Gov. Kasich for Signing SB 99 (The Cancer Treatment Modernization Act) into Law
International Myeloma Foundation Announces Affiliation with Korea Blood Cancer Association
International Myeloma Foundation’s 5th Annual IMWG Summit to Share Latest Myeloma Developments with Patients & Clinicians Around the World
IMF's Michael S. Katz Honored with ASCO's Partners in Progress Award
The IMF Reaches Out to Myeloma Patients in Italy
The International Myeloma Foundation Says Virotherapy Approach to Myeloma Could Lead to New Treatment Options
The International Myeloma Foundation (IMF) Applauds Gov. Beshear for Signing HB 126(The Cancer Treatment Modernization Act)Into Law
The International Myeloma Foundation Applauds Wisconsin Gov. Scott Walker for Signing SB 300 (The Cancer Treatment Fairness Act) into Law
The International Myeloma Foundation Says the Newest Myeloma Therapeutic Now Approved for Patients in Canada
Latest Myeloma Research, Live IMF Webcasts from American Society of Hematology Meeting
The International Myeloma Foundation announces partnership with Onyx Pharmaceuticals to support Black Swan Research Initiative®
IMF: NEWLY PUBLISHED STUDY SAYS PATIENTS IDENTIFIED WITH HIGH-RISK PRESYMPTOMATIC MYELOMA MAY BENEFIT FROM EARLY INTERVENTION
2013 Robert A. Kyle Lifetime Achievement Award Honors Prof. Gösta Gahrton
The International Myeloma Foundation to Convene First Global Leaders Summit in Stockholm to Raise Disease Awareness and Increase Access to Life-Saving Treatments
The International Myeloma Foundation Says Positive Recommendation by Regulatory Body Brings Myeloma Patients in Europe Closer to Accessing Latest Treatment
International Myeloma Foundation Honors Dr. Gösta Gahrton with 2013 Robert A. Kyle Lifetime Achievement Award
Patients Equal Access Coalition Applauds New Bill to Improve Access to Oral Cancer Drugs
The International Myeloma Foundation Launches the Black Swan Research Initiative™ to Develop the Very First Definitive Cure for Multiple Myeloma
Medical Innovation is Helping Patients Live Longer, Better Lives
The International Myeloma Foundation Says FDA Appoval of Kyprolis Gives Patients a Critical New Option
The International Myeloma Foundation Supports Patients Making Dramatic Pleas for New Drug Approvals
THE INTERNATIONAL MYELOMA FOUNDATION UNVEILS THE FIRST COMPREHENSIVE DISEASE-SPECIFIC CANCER APP FOR PATIENTS, DOCTORS AND CAREGIVERS
THE INTERNATIONAL MYELOMA FOUNDATION SAYS THREE STUDIES HIGHLIGHTING MYELOMA TREATMENT-ADVANCES ARE FEATURED TOGETHER IN THE PRESTIGOUS NEW ENGLAND JOURNAL OF MEDICINE
THE INTERNATIONAL MYELOMA FOUNDATION APPLAUDS DELAWARE AND VIRGINIA LEGISLATURES FOR PASSING ORAL DRUG PARITY BILL
THE INTERNATIONAL MYELOMA FOUNDATION SAYS POMALIDOMIDE, AN IMPORTANT NEW DRUG FOR PATIENTS, HAS BEEN SUBMITTED FOR FDA APPROVAL
FDA Recognition of Extended Survival with VELCADE® Indicates Important New Progress in Treating the Disease
The International Myeloma Foundation : Study Says Long-Term Maintenance Treatment Demonstrates 90% Overall Survival Rate
The International Myeloma Foundation Says Major Medical Meeting in Paris will Support New Treatment Options for Patients
The International Myeloma Foundation, Marking 20 Years of Serving the Myeloma Community, Applauds, Members of the International Myeloma Working Group for Their Body of Work Being Presented at the ASH Hematology Conference
Nurse Leaders within the International Myeloma Foundation Publish Book for Nurses to Help Myeloma Patients Optimize Their Care
The International Myeloma Foundation Says Study Suggests Carfilzomib Could be Important New Treatment Option for Relapsed Myeloma Patients
IMF supports legislation to require equitable insurance reimbursement for oral cancer drugs
Inaugural Summit of the International Myeloma Working Group Lays the Groundwork for a Course Toward a Cure.
ASCO Presentations Point to Longer Remissions, Fewer Transplants and Implications Beyond Myeloma
First Anniversary Of "Cancer Patient Statement Of Principles" Marks Initial Progress On Reimbursement Parity For Oral Cancer Drugs
The International Myeloma Foundation Supports Legislation to Require Equal Insurance Reimbursement for Oral Cancer Drugs
The International Myeloma Foundation Welcomes Entertainment Industry Executive Amy Weiss to Board of Directors
A Patient Advocacy Coalition Led by the International Myeloma Foundation and the MDS Foundation Says Its Cancer Patient Statement of Principles Gains Momentum Going into the ASH Cancer Conference
The International Myeloma Foundation Says New Study Suggests Possible Genetic Link between Environmental Toxins and Myeloma
The International Myeloma Foundation and the Mario A. Schirinzi Association of Central Italy Join Forces in the Fight Against Multiple Myeloma
The International Myeloma Foundation, the MDS Foundation and a Coalition of Patient Advocacy Organizations Call for Updated Rules for Reimbursement, Access and Approvals for New and Existing Cancer Treatments.
Statement from the IMF on Insurance Inequities
The International Myeloma Foundation Says Medicare Decision to Cover PET Scans Can Improve Disease Staging and Treatment Planning
The International Myeloma Foundation Says the Kennedy-Hutchison Cancer Bill Will Reinvigorate War on Cancer
Dr. Brian Durie Receives the Prestigious Waldenström's Award in Recognition of His Many Contributions to the Field of Multiple Myeloma
The International Myeloma Foundation – Webcasting Live from the Scientific Sessions at the XIIth International Myeloma Workshop
The International Myeloma Foundation Praises UK REVLIMID® Proposal as Positive, Innovative Model for Reimbursement
Continuing Her Husband's Work: The IMF Wants to End Myeloma
International Myeloma Foundation (IMF) Marches Toward a Cure with Takeda Oncology's 'Music 2 Fight Myeloma' Initiative for 'Myeloma ACTION Month'
OncLive: Project Aims to "Bridge the Gap" From Remission to Cure in Multiple Myeloma
Onclive: Charting the Course in Myeloma: Durie Keeps Standards, New Goals in Sight
Dr. Brian Durie Featured in BBC Radio Program "Food, Cancer and Well-Being"
When myeloma awareness goes mobile
IMF Advocates Join Thousands Rallying for Medical Research Support
IMF Chairman Dr. Brian Durie Interviewed on Sirius XM Radio's 'Oncology Show'
Patient Advocacy Message Hits Airwaves in Istanbul
Dr. Durie interviewed by the Wall Street Journal for article "New Drugs Slow a Fast-Spreading Cancer"
Dr. Durie interviewed by NPR for article on myeloma featuring patient and runner Don Wright
Susie Novis Interviewed by Patient Power on on the Latest Developments in Myeloma
Mozobil™ Approval Could benefit Myeloma Patients Undergoing Autologous Stem Cell Transplants
THE INTERNATIONAL MYELOMA FOUNDATION SAYS PATIENT EXPERIENCE—LONGER SURVIVAL AND IMPROVED QUALITY OF LIFE—SUPPORTS ENCOURAGING DATA BEING PRESENTED AT THE ANNUAL HEMATOLOGY MEETING
THE INTERNATIONAL MYELOMA FOUNDATION ANNOUNCES NEW THREE-WAY RESEARCH AGREEMENT WITH NOBEL PRIZE WINNER LUC MONTAGNIER AND HOWARD URNOVITZ OF CHRONIX BIOMEDICAL
THE INTERNATIONAL MYELOMA FOUNDATION CALLS FOR ALL PATIENTS TO HAVE ACCESS TO THE NOVEL THERAPIES FOR MYELOMA
THE INTERNATIONAL MYELOMA FOUNDATION CONGRATULATES FRIEND AND COLLABORATOR DR. LUC MONTAGNIER FOR BEING AWARDED THE NOBEL PRIZE
THE INTERNATIONAL MYELOMA FOUNDATION RECEIVES HEALTH IMPACT AWARD FOR EXCEPTIONAL SERVICE TO MYELOMA PATIENTS AND COMMUNITY
THE INTERNATIONAL MYELOMA FOUNDATION APPLAUDS EXPANSION OF VELCADE® FOR PREVIOUSLY UNTREATED PATIENTS IN EUROPE AND CANADA
THE INTERNATIONAL MYELOMA FOUNDATION SAYS LIFE-CHANGING BENEFITS OF REVLIMID® RECOGNIZED BY THE PRESTIGIOUS PRIX GALIEN USA AWARD 2008
THE INTERNATIONAL MYELOMA FOUNDATION SAYS JOURNAL EDITORIAL DOCUMENTS DRAMATIC INCREASE IN SURVIVAL SINCE THE 1980'S
THE INTERNATIONAL MYELOMA FOUNDATION SAYS PREVIOUSLY UNTREATED PATIENTS COULD BENEFIT FROM FDA APROVAL OF VELCADE® FOR 'FRONT-LINE' USE
THE INTERNATIONAL MYELOMA FOUNDATION SAYS NEW STUDIES SHOW LONGER SURVIVAL FOR MYELOMA PATIENTS AND IMPROVED RESPONSE TO TREATMENTS
NURSE LEADERSHIP BOARD OF THE INTERNATIONAL MYELOMA FOUNDATION FINALIZES GUIDELINES TO HELP NURSES MANAGE AND PATIENTS COPE WITH THE SIDE EFFECTS OF THERAPY
THE INTERNATIONAL MYELOMA FOUNDATION SAYS THALIDOMIDE APPROVAL IN EUROPE COULD PROVIDE SURVIVAL BENEFITS TO NEWLY DIAGNOSED MYELOMA PATIENTS
THE INTERNATIONAL MYELOMA FOUNDATION SAYS REVLIMID® MEETS IMPORTANT QUALITY OF LIFE MEASURES
IMF PRESENTS THE KYLE LIFETIME ACHIEVEMENT AWARD TO MARIO BOCCADORO, MD, OF THE UNIVERSITY OF TORINO, ITALY
THE IMF SAYS NEWLY DIAGNOSED PATIENTS COULD BENEFIT FROM FDA "PRIORITY REVIEW" OF VELCADE® FOR FRONT-LINE USE
THE INTERNATIONAL MYELOMA FOUNDATION SAYS NEW TREATMENT REGIMEN FOR OLDER PATIENTS COULD SOON BE APPROVED IN EUROPE
THE INTERNATIONAL MYELOMA FOUNDATION SAYS STUDY SHOWS 90% OVERALL RESPONSE FOR PATIENTS WITH NEW REVLIMID® COMBINATION
THE INTERNATIONAL MYELOMA FOUNDATION IDENTIFIES POTENTIAL LINK BETWEEN GENETIC PATHWAYS AND ENVIRONMENTAL RISKS FOR MYELOMA
THE INTERNATIONAL MYELOMA FOUNDATION SAYS NEW FINDINGS REPORTED AT GLOBAL CANCER CONFERENCE REQUIRE NEW WAYS TO EVALUATE TREATMENTS
Major Medical Conference Points to Improved Treatment and Survival Options for Blood Cancers
THE INTERNATIONAL MYELOMA FOUNDATION SAYS REVLIMID® EXTENDS SURVIVAL WITH POSITIVE IMPLICATIONS FOR A WIDE RANGE OF BLOOD CANCERS
THE INTERNATIONAL MYELOMA FOUNDATION SAYS NEW THALIDOMIDE DATA CONFIRMS SURVIVAL BENEFITS FOR OLDER PATIENTS
THE INTERNATIONAL MYELOMA FOUNDATION REPORTS THAT INTERIM FINDINGS FROM GLOBAL TRIAL EXTEND POSITIVE BENEFITS OF VELCADE TO NEWLY DIAGNOSED PATIENTS
The International Myeloma Foundation Issues Prevention and Treatment Guidelines for Firefighters for High-Risk Cancer
THE NURSE LEADERSHIP BOARD OF THE INTERNATIONAL MYELOMA FOUNDATION PRESENTS “GUIDELINES FOR ENHANCED PATIENT CARE” AT INTERNATIONAL MEDICAL MEETING
THE INTERNATIONAL MYELOMA FOUNDATION SAYS DATA REPORTED AT A GLOBAL MEDICAL MEETING IN GREECE DEMONSTRATES IMPROVED SURVIVAL FOR A WIDE RANGE OF MYELOMA PATIENTS
THE INTERNATIONAL MYELOMA FOUNDATION SAYS EMEA MARKETING APPROVAL OF REVLIMID® IS AN IMPORTANT ADVANCE FOR PATIENTS IN EUROPE
STUDY SHOWS VELCADE® PLUS DOXIL® IMPROVES SURVIVAL IN PREVIOUSLY TREATED PATIENTS WITH MYELOMA
New England Journal of Medicine Sites Myeloma as Concern for Firefighters at 9-11 Scene
THE INTERNATIONAL MYELOMA FOUNDATION REPORTS NEW DRUG COMBINATION - VELCADE® PLUS DOXIL® - APPROVED FOR MYELOMA
IMF REPORTS POSITIVE SHIFT IN TREATMENT PARADIGM FOR PATIENTS
THE INTERNATIONAL MYELOMA FOUNDATION SAYS CELGENE LAUNCHES NEW "PATIENT SUPPORT COORDINATOR" PROGRAM AT MEETING OF SUPPORT GROUP LEADERS IN PHOENIX
THE INTERNATIONAL MYELOMA FOUNDATION SAYS CLINICAL TRIAL RESULTS COULD IMPROVE SURVIVAL WHILE REDUCING SIDE EFFECTS FOR MANY PATIENTS
IMF Says Revlimid Approval Could Benefit Patients Throughout Europe
THE INTERNATIONAL MYELOMA FOUNDATION APPOINTS HEATHER COOPER ORTNER VICE PRESIDENT OF DEVELOPMENT
INDEPENDENT SURVEY RATES THE INTERNATIONAL MYELOMA FOUNDATION THE #1 RESOURCE FOR PATIENTS
LEADING CANCER EXPERTS TO CONDUCT LOS ANGELES SEMINAR ON MYELOMA TREATMENT AS THE "NEW MODEL" FOR CANCER CARE
The International Myeloma Foundation Unveils Plans for MYELOMA MOBILE to Travel Across the U.S. this Summer
BANK ON A CURE® "GENE BANK" RESEARCHERS IDENTIFY PATHWAYS THAT MEDIATE SIDE EFFECTS FROM WIDELY-USED MYELOMA TREATMENT
THE INTERNATIONAL MYELOMA FOUNDATION: MULTIPLE STUDIES AT GLOBAL CANCER CONFERENCE SHOW NEW THERAPIES CHANGING THE OUTLOOK FOR PATIENTS WITH BLOOD CANCERS
The International Myeloma Foundation Establishes First-of-a-Kind Partnership With Nurses to Enhance Patient Care
Leading Cancer Experts Conduct Philadelphia Seminar on MM Treatment as New 'Model' for Cancer Care
IMF DNA BANK IDENTIFIES GENETIC VARIATIONS RELATED TO PREDISPOSITION TO MM AND RESPONSE TO TX
New, Improved Staging System for Multiple Myeloma
Developed for Use Around the World
IMF to Bring Highlights from Prestigious International Myeloma Workshop to Myeloma Patients
IMF Receives Four-Star Rating from America's Largest Charity Evaluator
GREAT NEWS: Revlimid® Phase III Myeloma Trials to Be Unblinded Early!
IMF Applauds Medicare Decision to Expand PET Scan Coverage for Myeloma
Kenneth C. Anderson, MD to Receive the IMF's Robert A. Kyle Lifetime Achievement Award
IMF Receives Million Dollar Grant from Centers for Disease Control and Prevention
IMF Raises Awareness of Little Known Cancer During 3rd Annual Myeloma Awareness Week (August 20 -30)
International Myeloma Foundation Heralds ECOG Announcement
International Myeloma Foundation Supports Senator Hutchison Initiative
Foremost Myeloma Organization to Honor Dr. Bart Barlogie
Webcast of the Official Launch of BANK ON A CURE®
Bank On A Cure® Launch Press Release
Bank On A Cure® Questions & Answers
Bank On a Cure® Frequently Asked Medical Questions
Bank On A Cure® Scientific Advisory Board
International Myeloma Foundation Fact Sheet
IMF Patient Programs and Services
Bank On A Cure® Brian Van Ness, Ph.D.
Bank On A Cure® on the IMF Website
Brian G.M. Durie, M.D.
Chairman of the Board
Susie Novis Durie
President


You might also be interested in:

2016 Press Releases
The IMF’s International Myeloma Working Group Establishes Updated Yardstick for Disease Assessment in the Evolving Treatment Landscape of 2016

 New Categories of Minimal Residual Disease (MRD) Negativity

 Provide Clinical Trial Endpoints and Framework for Cure


International Myeloma Foundation Brings Together 100 of the World’s Top Myeloma Experts June 7-9, 2016 in Copenhagen for 7th Annual Summit

Addressing Rising Cost of Myeloma Treatments to Be a Key Focus


International Myeloma Foundation Honors Dr. S. Vincent Rajkumar With the 2016 Robert A. Kyle Lifetime Achievement Award

Given in Recognition of Significant Contributions to Myeloma Research and Patient Care


International Myeloma Foundation (IMF) Says Controversial Drug Cost Report Could Limit Patient Access to Optimal Treatment

 IMF Raises Red Flags in Advance of May 26 Hearing, Offers Alternate Approach


Everybody Loved Doris: An IMF Tribute

The IMF is deeply saddened by the passing of Doris Roberts on April 18, 2016. An Emmy-Award-winning actress, who starred in the classic sitcom “Everybody Loves Raymond,” Doris was an ardent supporter of Peter Boyle Memorial Fund. She generously delivered hilarious performances at the IMF’s Annual Comedy Gala since 2007. Everybody Loved Doris. Truly.

In her honor, we have created a Tribute revisiting some of her most memorable moments at the IMF Comedy Celebrations through the years. 


International Myeloma Foundation (IMF) Funds First Large-Scale Screening to Identify and Treat Precursor of Blood Cancer Before Disease Develops

 Prospective Data on How to Monitor MGUS Could Alter Myeloma Treatment Management


International Myeloma Foundation (IMF) Marches Toward a Cure with Takeda Oncology’s ‘Music 2 Fight Myeloma’ Initiative for ‘Myeloma ACTION Month’

In concert with the IMF’s March “Myeloma ACTION Month” campaign, Takeda Oncology is putting a musical spin on fundraising with “Music 2 Fight Myeloma,” which pairs the power of music with the impact of social media.


International Myeloma Foundation (IMF) Declares March Myeloma Action Month

 IMF’s Proactive Education Campaign Targets Primary Care Doctors, Lawmakers and Patients with Information and Events


The International Myeloma Foundation (IMF) Appoints Dr. Rafat Abonour as New Medical Liaison to Support Organization’s European Program Expansion

Myeloma expert Dr. Rafat Abonour as IMF Medical Liaison. Dr. Abonour’s appointment follows the foundation’s recent appointment of French myeloma researcher Prof. Jean-Luc Harousseau, MD. Both men will help accelerate the IMF’s mission to affect positive change around the world.


International Myeloma Foundation (IMF) Accelerates Global Expansion with Appointment of Prof. Jean-Luc Harousseau MD

Renowned researcher to help accelerate IMF programs in Asia and Europe


2015 Press Releases
Generous Donations Help Fund 2016 Brian D. Novis Research Grants

The IMF awarded its 2016 Brian D. Novis research grants in a ceremony Dec 5, 2015 at the 57th annual meeting of the American Society of Hematology (ASH) in Orlando, FL. For 20 years, the IMF has funded promising clinical investigators in the field of multiple myeloma from around the world through the generous donations of private individuals and IMF Member Fundraisers held across the country. Two very generous surprise donations will undoubtedly help move myeloma research even further ahead! 


International Myeloma Foundation Scores Support in Takeda Oncology’s ‘3 Points for Patients’ Campaign Partnership with NBA’s Boston Celtics

Every 3-Point Basket Will Trigger a Donation for IMF Research and Education


The International Myeloma Foundation (IMF) Announces Publication of New Diagnostic Guidelines to Better Assess Patients and Guide Treatment

Revisions to the International Staging System by the IMF’s International Myeloma Working Group Reported in the Journal of Clinical Oncology


Members of International Myeloma Foundation’s Nurse Leadership Board Author Key Textbook for Nurses

Book Updates the First Comprehensive Review by and For Nurses 


The International Myeloma Foundation Applauds Bipartisan Introduction of Oral Parity Legislation

Legislation Works to Increase Patient Access to Anticancer Medications


International Myeloma Foundation Brings Together 100 of the World’s Top Myeloma Experts June 8-10 in Vienna, Austria for 6th Annual Summit

Researchers, Clinicians and Advocates to Share Cutting-Edge Research To Improve Patients’ Lives and Lead to a Cure


The International Myeloma Foundation Mourns the Passing of Board of Directors Member, Patient Champion, Michael S. Katz

This weekend the IMF lost a founding Board member who brought myeloma patient advocacy to the forefront. "Susie and I lost a dear and wonderful friend,” said IMF Chairman Dr. Brian Durie. “Mike Katz routinely inspired patients to take charge of their myeloma—to understand what is going on and get questions answered. He was a colleague and friend to patients and physicians alike. Mike, we will all miss you, we love you and will remember you always."


The International Myeloma Foundation (IMF) Announces Another Successful Myeloma Awareness Month (#MAM)
The IMF launched March as “Myeloma Awareness Month” in 2009. Fueled by the organization’s key message that “knowledge is power,” the IMF this year spread information about the disease through local community events, social media campaigns, story sharing, and official proclamations. Advocates across 28 states, cities, and counties obtained proclamations, and Representative Brian Higgins (D-NY) introduced a federal resolution to recognize March 2015 as “National Multiple Myeloma Awareness Month.”

The International Myeloma Foundation (IMF) Secures the Introduction of a Federal Resolution Recognizing March 2015 as “National Multiple Myeloma Awareness Month”

Myeloma Awareness Month is wrapping up this year with the introduction of a national resolution (H. Res. 174) to designate March as "National Myeloma Awareness Month.” The resolution would add to the immense successes of patient advocates across the country who have already received proclamations for their individual states, counties, and cities. The resolution sponsor, Rep. Brian Higgins (D-NY), has been a strong ally of the IMF for the past several years, and has also been the lead sponsor of the Cancer Drug Coverage Parity Act since its inception in 2009. The IMF thanks Rep. Higgins for his leadership, along with the two other original sponsors, Rep. Eleanor Norton (D-NY) and Rep. Alcee Hastings (D-FL).


International Myeloma Foundation Honors Prof. Dr. Pieter Sonneveld With 2015 Robert A. Kyle Lifetime Achievement Award

The International Myeloma Foundation (IMF) — improving the quality of life of myeloma patients while working toward prevention and a cure — will present the 13th annual Robert A. Kyle Lifetime Achievement Award to Prof. Dr. Pieter Sonneveld during a ceremony in Vienna, Austria on June 9, 2015.


International Myeloma Foundation Declares March “Myeloma Awareness Month”
“Knowledge is Power” Is Key Message of Month-Long Awareness Campaign

It is officially Myeloma Awareness Month (?#‎MAM?)!

The IMF first declared this global event in 2009, with the notion that increasing awareness of the disease could lead to early diagnosis and increased funding for researching.

This year, we are pushing the "Knowledge is power" message.

"The majority of patients have never heard of myeloma before their diagnosis," IMF President and Co-Founder Susie Novis said. "The IMF is proud to lead the charge in raising myeloma awareness across America and around the world."


2014 Press Releases
International Myeloma Foundation Expresses Disappointment at Oncologic Drugs Advisory Committee (ODAC) Recommendation Against New Myeloma Treatment Panobinostat

On November 6, 2014 an FDA advisory panel, the Oncologic Drugs Advisory Committee (ODAC), held a hearing on panobinostat, a drug in development to treat relapsed myeloma. The committee voted not to recommend panobinostat for FDA approval. IMF staff members and myeloma patients testified on behalf of panobinostat, sharing the critical need for an array of treatment options for myeloma patients.


International Myeloma Foundation’s Research Division Issues New Guidelines for Early Diagnosis of Multiple Myeloma
The International Myeloma Foundation (IMF) – improving the quality of life of myeloma patients while working toward prevention and a cure – today announced that the organization’s research division, the International Myeloma Working Group (IMWG), has issued new criteria for diagnosing multiple myeloma. Myeloma is a cancer of cells in the bone marrow that affects the immune system and can damage bone.

Dr. Brian Durie, Chairman of the International Myeloma Foundation, Honored by Mayo Clinic With Distinguished Alumni Award

The International Myeloma Foundation (IMF) – improving the quality of life of myeloma patients while working toward prevention and a cure – congratulates its Chairman and Co-Founder Brian G.M. Durie, MD, on being honored with the Distinguished Alumni Award from Mayo Clinic. Dr. Durie, who completed residencies and fellowships at Mayo Clinic, was honored at a ceremony in Rochester, MN on October 20, 2014 for his “exceptional contributions” to the field of myeloma.


International Myeloma Foundation Hosts Congressional Briefing on Environmental Exposures, Such as Toxins at 9/11 World Trade Center Site, and Myeloma

The International Myeloma Foundation is hosting a briefing to discuss research on links between exposure to environmental factors and multiple myeloma.  Speakers at the briefing will discuss the latest research findings and share their personal stories about their experience with multiple myeloma.  The audience will learn about multiple myeloma, opportunities to further research, potential environmental risk factors for multiple myeloma, and efforts among patient advocates, industry, researchers and policy makers to reduce the exposure to environmental toxins associated with myeloma.


Study Results Published Showing Advantages with Revlimid in Newly Diagnosed Myeloma

The New England Journal of Medicine published a study this week showing that Revlimid (lenalidomide) plus low-dose dexamethasone improves survival and other measures of efficacy compared to MPT (melphalan, prednisone, and thalidomide) in newly diagnosed multiple myeloma patients who are not eligible for a stem cell transplant. The study also showed that continuing use of Revlimid-dexamethasone instead of stopping after a fixed number of treatments provided further advantages in multiple measures.


The International Myeloma Foundation (IMF) Celebrates Maine’s Oral Anticacer Treatment Access Law Taking Effect

The International Myeloma Foundation (IMF) – improving the quality of life of myeloma patients while working toward prevention and a cure –  today celebrates Maine’s Oral Anticancer Treatment Access Law taking effect. The law directs health benefit plans that provide coverage for cancer chemotherapy treatment to extend coverage for orally administered anticancer medications at a cost equal to the cost of intravenously administered or injected anticancer medications. 


The International Myeloma Foundation Unveils New Logo

Ushering in a new phase for the IMF and myeloma patients, the new logo reflects forward movement and hopefulness. This mirrors the significant progress being made in myeloma treatment, including the exceptional progress being made under the IMF’s signature Black Swan Research Initiative® to find a pathway to a cure for myeloma.


Freelite and Hevylite will help the Black Swan Research Initiative find the best treatment to cure multiple myeloma

Binding Site, a Birmingham, UK, based In-Vitro clinical diagnostic company, is pleased to announce that it has been chosen as an important diagnostic partner in the Black Swan ‘cure myeloma’ Research Initiative, sponsored by the International Myeloma Foundation (IMF).


The IMF says Imnovid® (pomalidomide), the newest medication for advanced cases of multiple myeloma, is approved for reimbursement in Sweden, Spain, and Switzerland

Imnovid (pomalidomide), called Pomalyst in the US, was recently approved for reimbursement in Sweden, Spain, and Switzerland. Myeloma patients in these countries who have exhausted all other therapeutics will now have access to Imnovid through their government health programs. “Through our Black Swan Research Initiative®, the IMF is working to find a cure for myeloma,” said Susie Novis, "but in the meantime we are pleased to see that new innovative treatments are becoming available to more patients worldwide, and the IMF continues to fight for patients where access is not yet available." 


The International Myeloma Foundation (IMF) Applauds Ohio Gov. Kasich for Signing SB 99 (The Cancer Treatment Modernization Act) into Law

The International Myeloma Foundation (IMF) – improving the quality of life of myeloma patients while working toward prevention and a cure – applauds Gov. John Kasich of Ohio for signing SB 99, The Cancer Treatment Modernization Act, into law. The bill requires that health plans regulated by the state that provide coverage for IV and oral anticancer treatments not exceed $100 copayment or coinsurance for a 30-day supply of orally administered anticancer treatment.


International Myeloma Foundation Announces Affiliation with Korea Blood Cancer Association

- Organizations Will Work Together to Support Myeloma Patients & Physicians in Korea

- IMF Adds to Its Growing Affiliations with Organizations around the World


International Myeloma Foundation’s 5th Annual IMWG Summit to Share Latest Myeloma Developments with Patients & Clinicians Around the World

- Summit Brings Together Global Myeloma Researchers, Clinicians, and Advocates

- IMWG Conference Series Live Stream Scheduled for June 11th


IMF's Michael S. Katz Honored with ASCO's Partners in Progress Award

Mr. Katz was chosen as this year’s recipient because of his efforts to raise awareness and education about myeloma in addition to his participation in the development of clinical trials of new drugs to treat this disease. He currently serves as vice president and as an executive board member of the International Myeloma Foundation (IMF) and is a member of the Eastern Cooperative Oncology Group’s (ECOG) Executive Committee.


The IMF Reaches Out to Myeloma Patients in Italy

The IMF continued its outreach to myeloma patients around the world by co-sponsoring a patient meeting in Bari, Italy, along with the Italian blood cancer patient group AIL Pazienti (Associazione Italiana contro le Leucemie, Linfomi e Mieloma).


The International Myeloma Foundation Says Virotherapy Approach to Myeloma Could Lead to New Treatment Options

-- Mayo Clinic Team Reports a Remission in Myeloma Patient Treated with a Massive Dose of Engineered Measles Virus

-- A New Path Forward in Myeloma Research Stirs Excitement in the Myeloma Community 


The International Myeloma Foundation (IMF) Applauds Gov. Beshear for Signing HB 126(The Cancer Treatment Modernization Act)Into Law

The International Myeloma Foundation (IMF) applauds Kentucky Gov. Steve Beshear for signing HB 126 (The Cancer Treatment Modernization Act) into law. The bill requires health plans regulated by the state that provide coverage for IV and oral anticancer treatments- to not exceed $100 copayment or coinsurance for a 30-day supply of orally administered anticancer treatment. 


The International Myeloma Foundation Applauds Wisconsin Gov. Scott Walker for Signing SB 300 (The Cancer Treatment Fairness Act) into Law

Today in Milwaukee cancer patient advocates, including myeloma Support Group members Linda Chowa and Mary Sandberg, at right, looked on as Wisconsin Governor Scott Walker signed the Cancer Treatment Fairness Act (SB 300) into law, making Wisconsin the 30th state to enact anticancer drug parity legislation. "This bill shows that our voices do indeed make a difference, because SB 300 was on its deathbed just three weeks ago, and today it is law," said Sue Enright, Midwest Director of Support Groups for the International Myeloma Foundation. "Thank you to every patient, family member, friend, healthcare professional and advocate who relentlessly stood with us throughout this long journey, and to our Wisconsin legislators who voted in favor of the bill." 


The International Myeloma Foundation Says the Newest Myeloma Therapeutic Now Approved for Patients in Canada
POMALYST® (Pomalidomide) - Previously Approved in the U.S. and Europe - Is an Oral Therapy with Demonstrated Overall Survival Benefit in Patients Who Have Had Multiple Prior Treatment

2013 Press Releases
Latest Myeloma Research, Live IMF Webcasts from American Society of Hematology Meeting

The International Myeloma Foundation says findings to be presented at this year's annual ASH meeting shed new light on when, how long and how much to treat myeloma patients.

–More Than 800 Myeloma Studies Will Be Featured at the 55th Annual Meeting of the American Society of Hematology (ASH)
–The IMF Will Present Several Educational and Informational Programs, and Update the Status of Its Groundbreaking Black Swan Research Initiative® to Find a Cure


The International Myeloma Foundation announces partnership with Onyx Pharmaceuticals to support Black Swan Research Initiative®

- Black Swan Research Initiative (BSRI®) Goal is Improving Treatment Options for Myeloma Patients 

- Onyx Partnership to Support Significant Research Initiative


IMF: NEWLY PUBLISHED STUDY SAYS PATIENTS IDENTIFIED WITH HIGH-RISK PRESYMPTOMATIC MYELOMA MAY BENEFIT FROM EARLY INTERVENTION

--The study from the PETHEMA Group in Spain Says an Oral Treatment Regimen “Significantly Delayed Time to Progression” with an Overall Survival Benefit in High-Risk Smoldering Myeloma--

 

--Study Published in the Prestigious New England Journal of Medicine--


2013 Robert A. Kyle Lifetime Achievement Award Honors Prof. Gösta Gahrton

In Recognition of Significant Contributions to Myeloma Research and Patient Care, the International Myeloma Foundation Honors Dr. Gösta Gahrton with the 2013 Robert A. Kyle Lifetime Achievement Award


The International Myeloma Foundation to Convene First Global Leaders Summit in Stockholm to Raise Disease Awareness and Increase Access to Life-Saving Treatments

Cancer Patient Advocate Leaders from 11 Countries Gather June 13th

Advocate from Turkey Says Patients Are Desperate for Mutual Support


The International Myeloma Foundation Says Positive Recommendation by Regulatory Body Brings Myeloma Patients in Europe Closer to Accessing Latest Treatment

--CHMP Recommendation for Pomalidomide Is Good News for Myeloma Patients in Europe--

--Pomalidomide (POMALYST® in the U.S.) Is an Oral Therapy FDA Approved in the United States for Patients Who Have Had Multiple Prior Treatments--

--The IMF Looks for Other Anti-Myeloma Agents Including KYPROLIS® (Carfilzomib) to Follow--


International Myeloma Foundation Honors Dr. Gösta Gahrton with 2013 Robert A. Kyle Lifetime Achievement Award

In Recognition of Significant Contributions to Myeloma Research and Patient Care


Patients Equal Access Coalition Applauds New Bill to Improve Access to Oral Cancer Drugs
The federal Cancer Drug Coverage Parity Act will dramatically improve the lives of cancer patients. Patients who previously could not afford these treatments will be able to access their life-saving effects. It will also make cancer treatments more practical for patients living in rural and underserved areas by reducing the need to drive long distances for a nurse or doctor to administer treatment.

The International Myeloma Foundation Launches the Black Swan Research Initiative™ to Develop the Very First Definitive Cure for Multiple Myeloma
An entirely new approach to monitoring treatment efficacy to achieve a cure.

Medical Innovation is Helping Patients Live Longer, Better Lives
Newly Approved POMALYST® (Pomalidomide) Is an Oral Therapy with Demonstrated Overall Survival Benefit in Patients Who Have Had Multiple Prior Treatments

2012 Press Releases
The International Myeloma Foundation Says FDA Appoval of Kyprolis Gives Patients a Critical New Option
Kyprolis (carfilzomib) Is First Approval of New Myeloma Drug in Six Years

The International Myeloma Foundation Supports Patients Making Dramatic Pleas for New Drug Approvals
Positive Development for Carfilzomib after Emotional Testimony by IMF Representatives

THE INTERNATIONAL MYELOMA FOUNDATION UNVEILS THE FIRST COMPREHENSIVE DISEASE-SPECIFIC CANCER APP FOR PATIENTS, DOCTORS AND CAREGIVERS

'Myeloma Post' Puts the Latest Medical Research, Physician Videos, Clinical Trials at Users' Fingertips.

CLICK TO DOWNLOAD THE APP.


THE INTERNATIONAL MYELOMA FOUNDATION SAYS THREE STUDIES HIGHLIGHTING MYELOMA TREATMENT-ADVANCES ARE FEATURED TOGETHER IN THE PRESTIGOUS NEW ENGLAND JOURNAL OF MEDICINE

– Studies Cover REVLIMID Continuous Therapy in Newly Diagnosed Myeloma Patients –

– And REVLIMID Maintenance Treatment Following Stem Cell Transplant –


THE INTERNATIONAL MYELOMA FOUNDATION APPLAUDS DELAWARE AND VIRGINIA LEGISLATURES FOR PASSING ORAL DRUG PARITY BILL

– Actions in Two States Represent the Latest in Line of Legislative Victories –
– Bills Equalize Reimbursements Insuring Cancer Patients Equal Access to New Wave of Life-Saving Treatments –


THE INTERNATIONAL MYELOMA FOUNDATION SAYS POMALIDOMIDE, AN IMPORTANT NEW DRUG FOR PATIENTS, HAS BEEN SUBMITTED FOR FDA APPROVAL

– Accelerated Review Could Make the Drug Available to Patients by Year End –


2011 Press Releases
FDA Recognition of Extended Survival with VELCADE® Indicates Important New Progress in Treating the Disease
5 Year Follow-Up of VISTA Trial Shows VELCADE Improves Overall Survival by More than a Year

The International Myeloma Foundation : Study Says Long-Term Maintenance Treatment Demonstrates 90% Overall Survival Rate

The International Myeloma Foundation Says Major Medical Meeting in Paris will Support New Treatment Options for Patients

2010 Press Releases
The International Myeloma Foundation, Marking 20 Years of Serving the Myeloma Community, Applauds, Members of the International Myeloma Working Group for Their Body of Work Being Presented at the ASH Hematology Conference

Nurse Leaders within the International Myeloma Foundation Publish Book for Nurses to Help Myeloma Patients Optimize Their Care

The International Myeloma Foundation Says Study Suggests Carfilzomib Could be Important New Treatment Option for Relapsed Myeloma Patients

IMF supports legislation to require equitable insurance reimbursement for oral cancer drugs

Inaugural Summit of the International Myeloma Working Group Lays the Groundwork for a Course Toward a Cure.

ASCO Presentations Point to Longer Remissions, Fewer Transplants and Implications Beyond Myeloma

First Anniversary Of "Cancer Patient Statement Of Principles" Marks Initial Progress On Reimbursement Parity For Oral Cancer Drugs

The International Myeloma Foundation Supports Legislation to Require Equal Insurance Reimbursement for Oral Cancer Drugs

The International Myeloma Foundation Welcomes Entertainment Industry Executive Amy Weiss to Board of Directors

2009 Press Releases
A Patient Advocacy Coalition Led by the International Myeloma Foundation and the MDS Foundation Says Its Cancer Patient Statement of Principles Gains Momentum Going into the ASH Cancer Conference

The International Myeloma Foundation Says New Study Suggests Possible Genetic Link between Environmental Toxins and Myeloma

The International Myeloma Foundation and the Mario A. Schirinzi Association of Central Italy Join Forces in the Fight Against Multiple Myeloma

The International Myeloma Foundation, the MDS Foundation and a Coalition of Patient Advocacy Organizations Call for Updated Rules for Reimbursement, Access and Approvals for New and Existing Cancer Treatments.

Statement from the IMF on Insurance Inequities

The International Myeloma Foundation Says Medicare Decision to Cover PET Scans Can Improve Disease Staging and Treatment Planning

The International Myeloma Foundation Says the Kennedy-Hutchison Cancer Bill Will Reinvigorate War on Cancer

Dr. Brian Durie Receives the Prestigious Waldenström's Award in Recognition of His Many Contributions to the Field of Multiple Myeloma

The International Myeloma Foundation – Webcasting Live from the Scientific Sessions at the XIIth International Myeloma Workshop

The International Myeloma Foundation Praises UK REVLIMID® Proposal as Positive, Innovative Model for Reimbursement

IMF in the News
Continuing Her Husband's Work: The IMF Wants to End Myeloma
Susie Novis Durie has a specific vision for the future of the International Myeloma Foundation (IMF), a group she co-founded in 1990 after her late husband Brian Novis was initially diagnosed with multiple myeloma.

International Myeloma Foundation (IMF) Marches Toward a Cure with Takeda Oncology's 'Music 2 Fight Myeloma' Initiative for 'Myeloma ACTION Month'
The International Myeloma Foundation (IMF) improving the quality of life of myeloma patients while working toward prevention and a cure is pleased to announce Takeda Oncology's initiative this month to raise funds for IMF myeloma research and advocacy. In concert with the IMF's March "Myeloma ACTION Month" campaign, Takeda Oncology is putting a musical spin on fundraising with "Music 2 Fight Myeloma," which pairs the power of music with the impact of social media.

OncLive: Project Aims to "Bridge the Gap" From Remission to Cure in Multiple Myeloma
ONCLive featured Dr. Brian Durie and the Black Swan Research Initiative.

Onclive: Charting the Course in Myeloma: Durie Keeps Standards, New Goals in Sight

Dr. Brian Durie Featured in BBC Radio Program "Food, Cancer and Well-Being"
U.K. food journalist Sheila Dillon interviewed cancer patients, nutritionists, and cancer doctors—including the IMF's Dr. Brian Durie—for "Food, Cancer and Well-Being," an episode of Dillon's weekly show,

When myeloma awareness goes mobile
The respected cancer publication CURE published a poignant blog written by Robin Tuohy, Director of Support Groups for the IMF. In it, Robin explores how her husband Michael's myeloma has affected their family—and how they've rallied together, not only to battle the disease, but to educate their community and beyond about myeloma.

IMF Advocates Join Thousands Rallying for Medical Research Support
The IMF was proud to be among several thousand researchers and patient advocates who gathered in Washington, D.C. on Monday, April 8, to protest cuts to biomedical research.

IMF Chairman Dr. Brian Durie Interviewed on Sirius XM Radio's 'Oncology Show'
Dr. Brian Durie discussed the IMF's exciting new Black Swan Research Initiative and the future of myeloma treatment during an hour-long interview on Sirius XM Satellite Radio's "Oncology Show." Hosted by NYU oncologists Abraham Chachoua, MD, and William L. Carroll, MD, the weekly show is broadcast from the lobby of Manhattan-based NYU Langone Medical Center.

Patient Advocacy Message Hits Airwaves in Istanbul
During the IMF's recent visit to Istanbul, Arin Assero, Vice President, Global Advocacy, was interviewed on Turkish television together with Dr. Mustafa Centiner, of the American Hospital in Istanbul. The topic was myeloma patient advocacy, which, in Turkey, centers around patient education, access to physicians and treatment, and encouraging patients to be a more proactive part of treatment decisions. Arin explained the IMF's role in patient support in English, which was then translated into Turkish by Dr. Centiner.

Dr. Durie interviewed by the Wall Street Journal for article "New Drugs Slow a Fast-Spreading Cancer"
Dr. Durie featured in Wall Street Journal article covering the recent approval of two new drugs which promise to extend life expectancy for myeloma patients.

Dr. Durie interviewed by NPR for article on myeloma featuring patient and runner Don Wright
In article titled "Targeted Cancer Drugs Keep Myeloma Patients Up And Running," Dr. Durie says the availability of these new drugs has been transformative.

Susie Novis Interviewed by Patient Power on on the Latest Developments in Myeloma
Susie Novis was interviewed by cancer survivor and former journalist Andrew Schorr for his health website PatientPower at the 2012 American Society of Hematology (ASH) meeting in Atlanta. In the interview, she says that we are "turning a corner" in myeloma with more good things to come.

Press Release Archive
Mozobil™ Approval Could benefit Myeloma Patients Undergoing Autologous Stem Cell Transplants
The FDA Has Granted Marketing Authority for Mozobil with Granulocyte-Colony Stimulating Factor in Patients with Multiple Myeloma and Non-Hodgkin’s Lymphoma

THE INTERNATIONAL MYELOMA FOUNDATION SAYS PATIENT EXPERIENCE—LONGER SURVIVAL AND IMPROVED QUALITY OF LIFE—SUPPORTS ENCOURAGING DATA BEING PRESENTED AT THE ANNUAL HEMATOLOGY MEETING
Treatment Progress Takes on New Urgency as Incidence of Myeloma Continues to Rise

THE INTERNATIONAL MYELOMA FOUNDATION ANNOUNCES NEW THREE-WAY RESEARCH AGREEMENT WITH NOBEL PRIZE WINNER LUC MONTAGNIER AND HOWARD URNOVITZ OF CHRONIX BIOMEDICAL
Will Study Circulating DNA as a Marker for and Potential Cause of Disease Recurrence

THE INTERNATIONAL MYELOMA FOUNDATION CALLS FOR ALL PATIENTS TO HAVE ACCESS TO THE NOVEL THERAPIES FOR MYELOMA
"We support efforts that put patients first… and work for better outcomes until there is a cure," Susie Novis, IMF President

THE INTERNATIONAL MYELOMA FOUNDATION CONGRATULATES FRIEND AND COLLABORATOR DR. LUC MONTAGNIER FOR BEING AWARDED THE NOBEL PRIZE
Renowned French Scientist Instrumental in Studying the Role of Viruses in Multiple Myeloma

THE INTERNATIONAL MYELOMA FOUNDATION RECEIVES HEALTH IMPACT AWARD FOR EXCEPTIONAL SERVICE TO MYELOMA PATIENTS AND COMMUNITY
The Wellsphere Health Impact Award honors individuals and organizations making the greatest impact in the lives of patients.

THE INTERNATIONAL MYELOMA FOUNDATION APPLAUDS EXPANSION OF VELCADE® FOR PREVIOUSLY UNTREATED PATIENTS IN EUROPE AND CANADA
With these new approvals, patients with multiple myeloma may now receive VELCADE earlier following an initial disease diagnosis.

THE INTERNATIONAL MYELOMA FOUNDATION SAYS LIFE-CHANGING BENEFITS OF REVLIMID® RECOGNIZED BY THE PRESTIGIOUS PRIX GALIEN USA AWARD 2008
The Prix Galien Award recognizes the technical, scientific and clinical research skills necessary to develop innovative medicines.

THE INTERNATIONAL MYELOMA FOUNDATION SAYS JOURNAL EDITORIAL DOCUMENTS DRAMATIC INCREASE IN SURVIVAL SINCE THE 1980'S
Writing in the October 10th edition of the Journal of Clinical Oncology, IMF chairman Brian G.M. Durie, M.D., notes that 25 years ago only 48 percent to 66 percent of myeloma patients survived two years, depending on which treatment was used. By contrast today, two-year survival rates are around 90 percent.

THE INTERNATIONAL MYELOMA FOUNDATION SAYS PREVIOUSLY UNTREATED PATIENTS COULD BENEFIT FROM FDA APROVAL OF VELCADE® FOR 'FRONT-LINE' USE
New Indication Provides Treatment-Free Interval As an Option

THE INTERNATIONAL MYELOMA FOUNDATION SAYS NEW STUDIES SHOW LONGER SURVIVAL FOR MYELOMA PATIENTS AND IMPROVED RESPONSE TO TREATMENTS
Encouraging new findings were presented at the American Society of Clinical Oncology (ASCO) meeting in Chicago, showing significant improvements in treating myeloma.

NURSE LEADERSHIP BOARD OF THE INTERNATIONAL MYELOMA FOUNDATION FINALIZES GUIDELINES TO HELP NURSES MANAGE AND PATIENTS COPE WITH THE SIDE EFFECTS OF THERAPY
Consensus Statements Will Be Published in the Clinical Journal of Oncology Nursing and Will Be Presented in Conjunction with the Oncology Nursing Society Annual Meeting May 16th

THE INTERNATIONAL MYELOMA FOUNDATION SAYS THALIDOMIDE APPROVAL IN EUROPE COULD PROVIDE SURVIVAL BENEFITS TO NEWLY DIAGNOSED MYELOMA PATIENTS
The European Commission Grants Marketing Authority for Melphalan-Prednisone-Thalidomide Regimen

THE INTERNATIONAL MYELOMA FOUNDATION SAYS REVLIMID® MEETS IMPORTANT QUALITY OF LIFE MEASURES

IMF PRESENTS THE KYLE LIFETIME ACHIEVEMENT AWARD TO MARIO BOCCADORO, MD, OF THE UNIVERSITY OF TORINO, ITALY
Founded the Italian Myeloma Study Group, a Pioneering Investigator Consortium in Europe

THE IMF SAYS NEWLY DIAGNOSED PATIENTS COULD BENEFIT FROM FDA "PRIORITY REVIEW" OF VELCADE® FOR FRONT-LINE USE
Priority review puts VELCADE on track for potential approval in mid-2008

THE INTERNATIONAL MYELOMA FOUNDATION SAYS NEW TREATMENT REGIMEN FOR OLDER PATIENTS COULD SOON BE APPROVED IN EUROPE
Positive Opinion from EU Advisory Committee Could Mark the Return of Thalidomide to Europe

THE INTERNATIONAL MYELOMA FOUNDATION SAYS STUDY SHOWS 90% OVERALL RESPONSE FOR PATIENTS WITH NEW REVLIMID® COMBINATION
BiRD Study (Biaxin®-Revlimid-Dexamethasone) Provides Evidence of Deep Complete Response Rates In Newly Diagnosed Multiple Myeloma

THE INTERNATIONAL MYELOMA FOUNDATION IDENTIFIES POTENTIAL LINK BETWEEN GENETIC PATHWAYS AND ENVIRONMENTAL RISKS FOR MYELOMA
BANK ON A CURE® DNA Data Base also finds Genetic Link to Bone Disease and Indications for Treatment

THE INTERNATIONAL MYELOMA FOUNDATION SAYS NEW FINDINGS REPORTED AT GLOBAL CANCER CONFERENCE REQUIRE NEW WAYS TO EVALUATE TREATMENTS
Survival and Longer Term Disease Control Take Precedence over Short Term Response to Treatment

Major Medical Conference Points to Improved Treatment and Survival Options for Blood Cancers
Findings to be presented at ASH show that even without a cure there are dramatic improvements in treatment and survival for patients with myeloma.

THE INTERNATIONAL MYELOMA FOUNDATION SAYS REVLIMID® EXTENDS SURVIVAL WITH POSITIVE IMPLICATIONS FOR A WIDE RANGE OF BLOOD CANCERS
Two Studies in the Prestigious New England Journal of Medicine Validate the Findings.

THE INTERNATIONAL MYELOMA FOUNDATION SAYS NEW THALIDOMIDE DATA CONFIRMS SURVIVAL BENEFITS FOR OLDER PATIENTS
Findings Could Support Marketing Authorization for thalidomide in Europe

THE INTERNATIONAL MYELOMA FOUNDATION REPORTS THAT INTERIM FINDINGS FROM GLOBAL TRIAL EXTEND POSITIVE BENEFITS OF VELCADE TO NEWLY DIAGNOSED PATIENTS
The combination therapy of VELCADE, melphalan and prednisone (VMP) demonstrates a significant advantage for patients newly diagnosed with myeloma. The therapy is already approved for use in patients who have received a previous treatment.

The International Myeloma Foundation Issues Prevention and Treatment Guidelines for Firefighters for High-Risk Cancer
For firefighters safety doesn’t end when the fire is over. Studies have shown firefighters are at higher risk for myeloma, and the risk increases with length of service. Most recently, studies linked an increased risk of myeloma to exposures at the World Trade Center site following 9/11.

THE NURSE LEADERSHIP BOARD OF THE INTERNATIONAL MYELOMA FOUNDATION PRESENTS “GUIDELINES FOR ENHANCED PATIENT CARE” AT INTERNATIONAL MEDICAL MEETING
NLB Poster at the International Myeloma Workshop Represents a Major Advance in Nursing Care. (Article includes PDF of poster.)

THE INTERNATIONAL MYELOMA FOUNDATION SAYS DATA REPORTED AT A GLOBAL MEDICAL MEETING IN GREECE DEMONSTRATES IMPROVED SURVIVAL FOR A WIDE RANGE OF MYELOMA PATIENTS
"Today we have multiple options for treatment, and for many patients survival is being measured in years, not months, with an excellent quality of life," says Susie Novis.

THE INTERNATIONAL MYELOMA FOUNDATION SAYS EMEA MARKETING APPROVAL OF REVLIMID® IS AN IMPORTANT ADVANCE FOR PATIENTS IN EUROPE
With today's action REVLIMID is now approved in Europe for myeloma patients who have received at least one prior therapy.

STUDY SHOWS VELCADE® PLUS DOXIL® IMPROVES SURVIVAL IN PREVIOUSLY TREATED PATIENTS WITH MYELOMA
Data Presented at the ASCO Cancer Conference

New England Journal of Medicine Sites Myeloma as Concern for Firefighters at 9-11 Scene
In an article entitled "The Legacy of the World Trade Center Dust," physicians say more than 5 years after the World Trade Center disaster, "uncertainty and controversy remain about the health risks posed by inhaling dust, the subsequent fires and the cleanup effort."

THE INTERNATIONAL MYELOMA FOUNDATION REPORTS NEW DRUG COMBINATION - VELCADE® PLUS DOXIL® - APPROVED FOR MYELOMA
Combination Provides 43% Improvement in Time to Disease Progression

IMF REPORTS POSITIVE SHIFT IN TREATMENT PARADIGM FOR PATIENTS
Second Closure of Multi-Center Trial in 4 Weeks Reinforces Benefits of Using REVLIMID® with Low Dose Steroids in Myeloma

THE INTERNATIONAL MYELOMA FOUNDATION SAYS CELGENE LAUNCHES NEW "PATIENT SUPPORT COORDINATOR" PROGRAM AT MEETING OF SUPPORT GROUP LEADERS IN PHOENIX
New Program Developed Following Meetings to Address Patient Questions and Concerns

THE INTERNATIONAL MYELOMA FOUNDATION SAYS CLINICAL TRIAL RESULTS COULD IMPROVE SURVIVAL WHILE REDUCING SIDE EFFECTS FOR MANY PATIENTS
Findings Show Survival Improvement with Lower Doses of Dexamethasone, the Steroid Commonly Used with REVLIMID® and other Drugs in Newly Diagnosed Myeloma

IMF Says Revlimid Approval Could Benefit Patients Throughout Europe
Patients, Advocates and Experts Applaud Positive Opinion from EU Advisory Committee

THE INTERNATIONAL MYELOMA FOUNDATION APPOINTS HEATHER COOPER ORTNER VICE PRESIDENT OF DEVELOPMENT
The International Myeloma Foundation (IMF) today announced the appointment of Heather Cooper Ortner as vice president of development. Heather comes to the IMF from the Brandeis-Bardin Institute where she was director of development for the past three years. Her appointment is effective immediately.

INDEPENDENT SURVEY RATES THE INTERNATIONAL MYELOMA FOUNDATION THE #1 RESOURCE FOR PATIENTS
The survey also found that the IMF excels in areas that matter most to patients: being extremely knowledgeable about issues related to myeloma, having up-to-date information, and putting the needs of patients and caregivers as the first priority.

LEADING CANCER EXPERTS TO CONDUCT LOS ANGELES SEMINAR ON MYELOMA TREATMENT AS THE "NEW MODEL" FOR CANCER CARE
"Blood cancers, including myeloma, are the third most common form of cancer, and today new therapies are transforming the way we treat them," said Susie Novis, president and co-founder of the International Myeloma Foundation. "While the benefits from most cancer treatment are measured in months, we are seeing many of our patients experience long-term responses measured in years with new I.V. and oral medications."

The International Myeloma Foundation Unveils Plans for MYELOMA MOBILE to Travel Across the U.S. this Summer
Michael Tuohy, a 7-year Cancer Survivor, Diagnosed When He Was Just 36, Will Travel with His Wife and Children. Communities Who Would Like a Visit May Contact the IMF.

BANK ON A CURE® "GENE BANK" RESEARCHERS IDENTIFY PATHWAYS THAT MEDIATE SIDE EFFECTS FROM WIDELY-USED MYELOMA TREATMENT
Findings Explain Why Certain Patients Suffer Blood Clots from Thalidomide; and Why Aspirin Works as an Intervention

THE INTERNATIONAL MYELOMA FOUNDATION: MULTIPLE STUDIES AT GLOBAL CANCER CONFERENCE SHOW NEW THERAPIES CHANGING THE OUTLOOK FOR PATIENTS WITH BLOOD CANCERS
Collectively, these studies represent a significant increase in knowledge of how myeloma responds to treatment, which is already becoming applicable to other cancers.

The International Myeloma Foundation Establishes First-of-a-Kind Partnership With Nurses to Enhance Patient Care
Nursing Leadership Board Will Provide Education, Updates and Reviews of Medical Protocols and Trends in Supportive Care.

Leading Cancer Experts Conduct Philadelphia Seminar on MM Treatment as New 'Model' for Cancer Care
The International Myeloma Foundation -- a not-for-profit organization supporting research and providing education, advocacy and support for myeloma patients, families, researchers and physicians -- is bringing leading experts to the Doubletree Hotel, August 4th and 5th, to discuss the latest trends and developments changing the face of cancer care. These new developments include the recent approval of the once controversial drug thalidomide for multiple myeloma, the anticipated approval this month of a related drug called Revlimid, and new survival data, just released at a scientific conference.

IMF DNA BANK IDENTIFIES GENETIC VARIATIONS RELATED TO PREDISPOSITION TO MM AND RESPONSE TO TX
The findings,presented at the 47th Annual Meeting of the American Society of Hematology (ASH), identify individual genetic differences that may be associated with risk factors for developing myeloma and with adverse reactions to therapies in patients who have myeloma.

New, Improved Staging System for Multiple Myeloma
Developed for Use Around the World
A new study published today on-line on the Journal of Clinical Oncology’s web site demonstrates the effectiveness of a new staging system for multiple myeloma, a cancer of the plasma cells in the bone marrow.  The new International Staging System (ISS) provides a simple prognostic factor alternative to the Durie and Salmon clinical staging system used for more than 25 years.  The collaborative efforts of the IMF International Myeloma Working Group led to the development the ISS after more than four years

IMF to Bring Highlights from Prestigious International Myeloma Workshop to Myeloma Patients
The IMF will be reporting highlights of the prestigious 10th International Myeloma Workshop, the premiere meeting regarding multiple myeloma. The Workshop is being held April 10-14 in Sydney, Australia. 

IMF Receives Four-Star Rating from America's Largest Charity Evaluator
The IMF is proud to have received a four-star rating of “Exceptional”  from Charity Navigator. The four-star rating, the highest rating available from the organization, indicates that the IMF “exceeds industry standards and outperforms most charities in its Cause.”

GREAT NEWS: Revlimid® Phase III Myeloma Trials to Be Unblinded Early!
Celgene Corporation reported that Revlimid, also known as lenalidomide, has shown outstanding results in the treatment of relapsed or refractory myeloma in two Phase III clinical trials.

IMF Applauds Medicare Decision to Expand PET Scan Coverage for Myeloma
“The IMF is extremely pleased that Medicare has expanded coverage for PET scans for myeloma patients in certain circumstances,” said Brian Durie, M.D., IMF Chairman. “We have worked hard for reimbursement because we believe PET scanning is an important tool for diagnostic evaluation, staging, and monitoring for myeloma. This is a very encouraging decision by Medicare, and an important step forward for myeloma patients.”

Kenneth C. Anderson, MD to Receive the IMF's Robert A. Kyle Lifetime Achievement Award
Dr. Anderson is being honored for pioneering critical advances against multiple myeloma, leading not only to improved treatments, but also to a deeper understanding of how myeloma occurs at the basic level of cells and genes.

IMF Receives Million Dollar Grant from Centers for Disease Control and Prevention
CDC Recognizes Excellence of Current IMF Programs, Funds Expansion of Existing Programs

IMF Raises Awareness of Little Known Cancer During 3rd Annual Myeloma Awareness Week (August 20 -30)
The IMF believes that raising awareness in the medical professions about multiple myeloma is a critical step toward early diagnosis and encouraging the development of new treatments.

International Myeloma Foundation Heralds ECOG Announcement
Phase III (E1 A00) Study Results Presented at ASCO

International Myeloma Foundation Supports Senator Hutchison Initiative
Program Recognizes Geraldine Ferraro’s Contributions

Foremost Myeloma Organization to Honor Dr. Bart Barlogie
Cancer Research Pioneer is Lifetime Achievement Award Recipient

Bank On A Cure® Press Kit
NEW YORK (May 9, 2005) –The International Myeloma Foundation (IMF) today announces the launch of Bank On A Cure®, the first myeloma-specific, cancer-patient DNA bank in history. Bank On A Cure was created to advance research, to provide better treatments in the short term, and to find a cure for multiple myeloma, a cancer of the plasma cells in the bone marrow.
Webcast of the Official Launch of BANK ON A CURE®
On May 9, 2005, the IMF and the Honorable Geraldine Ferraro officially launched Bank On A Cure®, the first myeloma-specific, cancer-patient DNA bank in history. Ms. Ferraro was diagnosed with myeloma in 1998.

Bank On A Cure® Launch Press Release
International Myeloma Foundation Launches World’s First DNA Database for Myeloma Patients
Geraldine Ferraro Donates DNA Sample to Bank On A Cure

Bank On A Cure® Questions & Answers
Taking the Guesswork Out of Myeloma

Bank On a Cure® Frequently Asked Medical Questions
What is myeloma? How will Bank On A Cure® affect treatment? What is DNA? What is a gene? What is a SNP? And many more questions.

Bank On A Cure® Scientific Advisory Board
Bank On A Cure has a distinguished international scientific advisory board.

International Myeloma Foundation Fact Sheet
Established in 1990 by Brian and Susie Novis and Dr. Brian G.M. Durie, the IMF is the world’s first non-profit organization dedicated to multiple myeloma research, patient support, education, and advocacy.

IMF Patient Programs and Services
The International Myeloma Foundation (IMF) provides invaluable support for patients and families dealing with multiple myeloma through comprehensive education, advocacy and support initiatives.

Bank On A Cure® Brian Van Ness, Ph.D.
Brian Van Ness, Ph.D., is co-director of the International Myeloma Foundation’s Bank On A Cure®, the world’s first databank of myeloma patient DNA and information. He is also professor and head of the Department of Genetics, Cell Biology and Development at the University of Minnesota Cancer Center in Minneapolis, Minn. His research focuses on exploring how different genes can influence disease progression and therapeutic response, particularly with regard to multiple myeloma.

Bank On A Cure® on the IMF Website
During the last decade scientists mapped the human genome providing a bridge to understanding human DNA. During the first decade of this century the International Myeloma Foundation will cross that bridge by pioneering the first global myeloma-specific DNA bank in history: Bank On A Cure®.

Media Kit
Brian G.M. Durie, M.D.
Chairman of the Board

Susie Novis Durie
President